Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.

116.27 3.02 +2.67%
Market cap
$23.0B
P/E
13.9×
Fwd P/E
58.4×
Dividend yield
—
F-score
9/9
Altman Z
8.57
Beneish M
−2.43
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
13.94 12.89 14.97 13.86

+8 more quarters

P/S ratio
3.90 3.50 3.75 3.45
P/FCF ratio
12.02 13.20 14.50 14.16
P/Operating CF
44.74 50.80 35.49 29.67
P/B ratio
3.58 3.34 3.73 3.57
EV/Sales
3.13 2.76 3.06 2.85
EV/EBITDA
9.71 8.67 9.79 8.72
EV/FCF
9.64 10.41 11.84 11.70
Current Ratio
4.59 3.68 3.32 3.20
Net Debt/EBITDA
(6.22) (12.27) (9.87) (6.20)
Debt/Equity
0.00 0.01 0.01 0.01
Earnings Yield
7.17% 7.76% 6.68% 7.22%
Free Cash Flow Yield
8.32% 7.57% 6.90% 7.06%
Free Cash Flow per Share
2.47 1.78 2.67 2.66
Book value per Share
31.66 28.21 26.47 23.77
Free Cash Flow
495.25 354.15 521.42 519.64
EV/EBIT
10.24 9.18 10.39 9.26
Other line items

Show all line items

Columns are period end dates